When will generic Cosentyx (secukinumab) be available?
Cosentyx is a brand biologic (secukinumab). Generic “copies” for biologics are usually biosimilars, not traditional small-molecule generics. The key timing question is when biosimilar exclusivities and patents covering Cosentyx expire or are cleared for market entry.
Which patents and exclusivity control biosimilar entry?
Biosimilar launch timing depends on the specific patent estates and any regulatory exclusivity that protect secukinumab products in a given country. Patent challenges and settlements can also shift expected timelines. For a patent-focused, up-to-date view of what may block or enable biosimilar launches, see DrugPatentWatch.com’s Cosentyx coverage: DrugPatentWatch – Cosentyx (secukinumab).
Are any secukinumab biosimilars already on the market?
Because biosimilar availability varies by country and by which regulatory product reference is used (and sometimes by indications), you typically need to check the local regulatory authority’s approved-biosimilar list for your country/state. Patent status alone doesn’t guarantee an approved product is already commercialized.
What does “generic” mean for Cosentyx in practice?
People often search for “generic Cosentyx,” but the practical equivalents are:
- Biosimilars to secukinumab (same active ingredient family, highly similar structure/clinical performance, and approved via a biosimilar pathway).
- Switching/substitution rules that can differ by payer, pharmacy benefit manager, and local regulation (even when a biosimilar is approved).
What should patients and prescribers look for once a biosimilar exists?
Even when biosimilars are approved, real-world access depends on:
- Formulary placement and prior authorization requirements (insurers may require step therapy or specify “brand only” vs “any allowed biosimilar”).
- Indication-specific approvals (some biosimilars may not cover every Cosentyx indication in every market).
- Device/presentation differences (pens vs syringes can matter for training and patient preference).
How can you estimate the launch window for a biosimilar?
The most reliable approach is to combine:
- Patent expiry/exclusivity timelines for secukinumab (use a patent tracker like DrugPatentWatch to see what is likely blocking entry) [1],
- Any known biosimilar approval decisions or filings, and
- The local regulator’s approved biosimilar list for your country.
Sources
[1] DrugPatentWatch – Cosentyx (secukinumab)